Who Paid My Doc Search
Menu
Organisation paid for research Program year 2025 Source: CMS Open Payments

Imic Inc

Neither a doctor nor a teaching hospital

Research payments

$6,823,282

1,315 payments

Through program year 2025, Imic Inc is reported as receiving $6,823,282 in research payments, across 1,315 payments.

By program year

7 rows
Year Kind Amount Payments
2025 Research $621,472 36
2024 Research $1,210,541 77
2023 Research $1,041,188 197
2022 Research $1,075,337 182
2021 Research $558,968 62
2020 Research $820,534 195
2019 Research $1,495,242 566

Breakdown

Who paid Research payments · program years 2019–2025
  1. GlaxoSmithKline, LLC. $1,552,161 55 payments
  2. Eisai Inc. $1,316,019 602 payments
  3. Eli Lilly and Company $1,251,140 51 payments
  4. AbbVie, Inc. $744,085 62 payments
  5. Gilead Sciences, Inc. $344,202 33 payments
  6. Genentech, Inc. $281,315 60 payments
  7. Hikma Pharmaceuticals USA $217,569 9 payments
  8. Regeneron Pharmaceuticals, Inc. $200,088 214 payments
  9. Celgene Corporation $182,410 8 payments
  10. Chiesi USA, Inc. $129,482 51 payments
Studies the money was for Research payments · program years 2019–2025
  1. A Phase 2, Parallel Group, Randomized, Double-Blind, Placebo-Controlle $1,552,161 55 payments
  2. A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease $842,322 548 payments
  3. Assessment of Safety, Tolerability, and Efficacy of Ly3372689 in Early Symptomatic Alzheimer's Disease $657,830 4 payments
  4. A Placebo-Controlled, Double-Blind, Parallel-Group, 18-Month Study With an Open-Label Extension Phase to Confirm Safety and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease $473,697 54 payments
  5. A Study to Assess Safety of ABBV-916 and How Intravenous ABBV-916 Moves Through Body and Affects Brain Amyloid Plaque Clearance in Adult Participants (Aged 50-90 Years) With Early Alzheimers Disease $279,674 3 payments
  6. Phase III Study of Balovaptan in Adults With Asd $238,600 28 payments
  7. Fluticasone Salmeterol Powder, 100mcg50mcg Multicenter Clinical Endpoint Study $170,128 7 payments
  8. A Multiple-Dose, Dose-Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Ly3372993 in Participants With Alzheimer's Disease $154,894 6 payments
  9. A Study to Assess Safety of ABBV-916 and How Intravenous ABBV-916 Moves Through Body and Affects Brain Amyloid Plaque Clearance in Adult Participants (Aged 50-90 Years) With Early Alzheimer's Disease $151,085 7 payments
  10. Assessment of Safety Tolerability and Efficacy of Ly3372689 in Early Symptomatic Alzheimer's Disease $149,807 2 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record